Send to a Friend Font Size: Increase Decrease

OrbiMed Advisors

OrbiMed Advisors's Portfolio

Last Updated on 5/16/11 @ 11:13am

Ticker	# of Shares	Price	Value
	73,114,592	$195.32	$14,280,742,110
	22,362,850	$195.32	$4,367,911,862
	17,233,668	$195.32	$3,366,080,034
	14,567,176	$195.32	$2,845,260,817
	9,033,726	$195.32	$1,764,467,363
	8,998,338	$195.32	$1,757,555,379
	8,322,140	$195.32	$1,625,480,385
	8,009,729	$195.32	$1,564,460,269
	7,619,135	$195.32	$1,488,169,449
View Additional Portfolio Information »

http://www.orbimed.com/OrbiMed is the world's largest healthcare-dedicated investment firm, with approximately $5 billion in assets under management. The firm was stated in 1989 with a vision to invest across the spectrum of healthcare companies: from private start-ups to large multinational companies.

Login to help us fill in information about this entity.

View Older Stories View More Recent Stories

Oct 22, 2019 08:38AM PlacementTracker Publishes Q3 2019 PIPE and Private Placement Markets League Tables
Oct 7, 2019 06:00AM Innovate Biopharmaceuticals to Merge with RDD Pharma Creating New Gastroenterology Company Focused on Specialty, Rare and Orphan Diseases
Sep 30, 2019 07:00AM Poul Sorensen Receives the 2019 Bloom Burton Award
Sep 25, 2019 04:42PM Form SC 13D SpringWorks Therapeutics Filed by: ORBIMED ADVISORS LLC
Sep 18, 2019 04:17PM Form SC 13D BELLUS Health Inc. Filed by: ORBIMED ADVISORS LLC
Sep 17, 2019 09:00AM Edgewise Therapeutics Closes $50 Million Series B Financing
Sep 12, 2019 04:43PM Form 3 SpringWorks Therapeutics For: Sep 12 Filed by: ORBIMED ADVISORS LLC
Sep 9, 2019 02:05PM Form SC 13D/A AVEDRO INC Filed by: ORBIMED ADVISORS LLC
Sep 9, 2019 09:09AM BELLUS Health Closes US$70 Million Public Offering of Common Shares in Canada and the United States
Aug 20, 2019 09:00AM Emendo Biotherapeutics Achieves Milestone of Collaboration with Takeda for its OMNI Nuclease Program
Aug 20, 2019 09:00AM Graybug Vision Secures $80 million of Additional Funding to Advance its Potentially Transformative Retina and Glaucoma Clinical Programs
Aug 20, 2019 09:00AM Emendo Biotherapeutics Achieves Milestone of Collaboration with Takeda for its OMNI Nuclease Program
Aug 15, 2019 04:05PM Sinovac Reports Unaudited Second Quarter 2019 Financial Results
Aug 14, 2019 04:58PM Form 13F-HR ORBIMED ADVISORS LLC For: Jun 30
Aug 14, 2019 04:38PM Form SC 13D/A Ascendis Pharma A/S Filed by: ORBIMED ADVISORS LLC
Aug 13, 2019 05:12PM Form SC 13D/A ViewRay, Inc. Filed by: ORBIMED ADVISORS LLC
Aug 12, 2019 05:16PM Form SC 13D/A SYNLOGIC, INC. Filed by: ORBIMED ADVISORS LLC
Aug 12, 2019 06:02AM Form SC 13D/A Alector, Inc. Filed by: ORBIMED ADVISORS LLC
Aug 8, 2019 04:59PM Form 4 Corvus Pharmaceuticals, For: Aug 06 Filed by: ORBIMED ADVISORS LLC
Aug 7, 2019 04:07PM Natera Reports Second Quarter 2019 Financial Results
Jul 23, 2019 08:38AM PlacementTracker Publishes Q2 2019 PIPE and Private Placement Markets League Tables
Jul 2, 2019 04:29PM Form SC 13D/A Corvus Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
Jul 1, 2019 06:16PM Form 4 Corvus Pharmaceuticals, For: Jun 27 Filed by: ORBIMED ADVISORS LLC
Jun 27, 2019 01:20PM Form SC 13D Prevail Therapeutics Filed by: ORBIMED ADVISORS LLC
Jun 19, 2019 06:36PM Form 3 Prevail Therapeutics For: Jun 19 Filed by: ORBIMED ADVISORS LLC
Jun 18, 2019 09:52PM OrbiMed Comments on Takeda Pharmaceutical Company Limited Proxy Ahead of 143rd Ordinary General Meeting of Shareholders 2019
Jun 18, 2019 08:37AM Arix Bioscience plc: Imara Presents initial Phase 2a data for IMR-687
Jun 13, 2019 09:00AM PMV Pharma Appoints Deepika Jalota, Pharm.D. as Senior Vice President and Head of Regulatory Affairs
Jun 12, 2019 08:00AM Prelude Therapeutics Secures $60 Million and Expands Management Team to Develop Drugs Targeting Novel Molecular Mechanisms in Cancer
May 22, 2019 12:44PM Form 4 Principia Biopharma Inc. For: May 21 Filed by: ORBIMED ADVISORS LLC
May 21, 2019 11:03AM Form SC 13D NextCure, Inc. Filed by: ORBIMED ADVISORS LLC
May 15, 2019 04:44PM Form 13F-HR ORBIMED ADVISORS LLC For: Mar 31
May 13, 2019 07:32PM Form 4 NextCure, Inc. For: May 13 Filed by: ORBIMED ADVISORS LLC
May 9, 2019 04:12PM Natera Reports First Quarter 2019 Financial Results
May 9, 2019 07:25AM Alpine Immune Sciences Provides Corporate Update and Reports First Quarter 2019 Financial Results
May 7, 2019 08:00AM Kyn Therapeutics Strengthens Leadership Team with Key Appointments
Apr 29, 2019 01:11PM Emendo Biotherapeutics Enters Into Licensing Option Agreement With Takeda for its OMNI Nuclease Program
Apr 29, 2019 01:11PM Emendo Biotherapeutics Enters Into Licensing Option Agreement With Takeda for its OMNI Nuclease Program
Apr 24, 2019 06:17PM Form 4 Turning Point Therapeuti For: Apr 22 Filed by: ORBIMED ADVISORS LLC
Apr 24, 2019 05:29PM Form SC 13D Turning Point Therapeuti Filed by: ORBIMED ADVISORS LLC
Apr 24, 2019 09:00AM Emendo Biotherapeutics Enters Into Licensing Option Agreement With Takeda for its OMNI Nuclease Program
Apr 19, 2019 02:20PM Form SC 13G X4 Pharmaceuticals, Inc Filed by: ORBIMED ADVISORS LLC
Apr 16, 2019 07:04PM Form 3 Turning Point Therapeuti For: Apr 16 Filed by: ORBIMED ADVISORS LLC
Apr 16, 2019 08:38AM PlacementTracker Publishes Q1 2019 PIPE and Private Placement Markets League Tables
Apr 9, 2019 01:45PM Form SC 13D/A Tricida, Inc. Filed by: ORBIMED ADVISORS LLC
Apr 4, 2019 05:01PM Form SC 13D/A Xtant Medical Holdings, Filed by: ORBIMED ADVISORS LLC
Apr 3, 2019 01:07PM Form 4 Xtant Medical Holdings, For: Apr 01 Filed by: ORBIMED ADVISORS LLC
Apr 1, 2019 08:30AM Xtant Medical Announces Amendments and Extension of Credit Facility
Mar 25, 2019 05:13PM Form SC 13D/A resTORbio, Inc. Filed by: ORBIMED ADVISORS LLC
Mar 19, 2019 04:58PM Form SC 13D/A X4 Pharmaceuticals, Inc Filed by: ORBIMED ADVISORS LLC

View More Recent Stories View Older Stories

Nasdaq		15000.33
	+57.68	(+0.39%)

S&P 500		4486.55
	+7.02	(+0.16%)

Market Snapshot

Free News Feed